BMRN Assumes by UBS -- Price Target Lowered to $88.00
UBS analyst Joon Lee lowered BioMarin Pharmaceutical's (BMRN) price target to $88.00 from $114.00, a 22.81% reduction, while maintaining a 'Buy' rating. The stock is trading at $56.05, which is 36.5% undervalued compared to its GF Value™ of $88.30. BioMarin has a GF Score™ of 73/100, indicating solid performance relative to peers, but shows mixed insider and institutional activity.
How this was made
The 30-second read
Why it matters
The downgrade could trigger short‑term selling pressure but may not affect long‑term growth prospects tied to its pipeline.
Market read
Analyst target cut is a fresh catalyst that may influence BMRN's near‑term price action.
What to watch
Potential upcoming clinical data releases could offset the target reduction.
Background
BioMarin is a mid‑cap biotech focused on rare disease therapies. The price target cut follows a broader market pullback in biotech valuations.
Ticker impact
UBS analyst cut BioMarin's price target to $88 from $114, a 22.8% reduction.
likely downward pressure as investors price in the lower target
Analyst target cuts historically precede short-term price declines, especially when the cut is sizable.
Market effects
May weigh on other biotech stocks as analysts reassess valuations.
Limited to US biotech sector.
Minimal global impact.
Counterpoint
Some investors may view the cut as an overreaction and look for buying opportunities.
Key entities
- AnalystUBS
Issued the price target reduction.
- CompanyBioMarin Pharmaceutical Inc.
Subject of the analyst rating update.
